 LAUSANNE, Switzerland--BUSINESS WIRE--ADC Therapeutics SA NYSE:ADCT, a commercial-stage biotechnology company leading the development of novel antibody drug conjugates ADCs to treat hematological malignancies and solid tumors, announced today that posters on four ZYNLONTATM loncastuximab tesirine-lpyl clinical trials were presented at the 16th Annual International Conference on Malignant Lymphoma ICML. The updated results from our pivotal LOTIS-2 clinical trial presented at ICML conti 